Researchers have observed that using a special type of monoclonal antibody drug that blocks the integrin beta6-TGF-beta pathway, prevents pulmonary fibrosis (scarring of the lungs), a side effect of radiation therapy in lung cancer patients, thereby extending patient's lives and improving their quality of life. The study was presented at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
"The toxicity of pulmonary fibrosis limits the amount of the radiation dose that can be safely given to patients," said Simon Cheng, M.D., Ph.D., an author of the study and a radiation oncologist at New York University Medical Center in New York. "These study results may lead to more effective radiation therapies for advanced lung cancer, which is the leading cause of cancer deaths in the U.S."
More than 50 percent of patients receiving radiation therapy for advanced lung cancer develop radiation-induced lung fibrosis, a painful side effect that can affect patients' quality of life and, in some cases, can be fatal. Pulmonary (lung) fibrosis involves inflammation and scarring of the lungs causing patients to feel short of breath, have a chronic dry cough, feel fatigue and pain in the chest, and suffer loss of appetite and weight loss. Over time, fibrosis causes the air sacs of the lungs to be replaced by scar tissue, causing difficulty breathing and an irreversible loss of the tissue's ability to transfer oxygen into the bloodstream.
"Fibrosis is a very serious side effect that often keeps doctors from giving patients a full dose of radiation for fear that the serious problems caused by fibrosis will outweigh the good done by the radiation. If further studies conclude that this drug can indeed prevent fibrosis in lung cancer patients, I believe researchers are a huge step closer to curing this disease," said Dr. Cheng.